Tesaro Announces Participation in Three Investor Conferences
Nov 21, 2016 21:05 pm UTC| Business
WALTHAM, Mass., Nov. 21, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are: The...
Corium Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Highlights
Nov 21, 2016 21:02 pm UTC| Business
MENLO PARK, Calif., Nov. 21, 2016 -- Corium International,Inc.(Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products,...
FBR to Host 23rd Annual Investor Conference
Nov 21, 2016 21:01 pm UTC| Business
ARLINGTON, Va., Nov. 21, 2016 -- FBR Co. (Nasdaq:FBRC) (“FBR” or the “Company”), a leading investment bank serving the middle market, will host its 23rd Annual Investor Conference in New York at the Westin Times Square...
Aspen Group to Present at the 9th Annual LD Micro Main Event
Nov 21, 2016 21:01 pm UTC| Business
NEW YORK, Nov. 21, 2016 -- Aspen Group, Inc. (OTCQB:ASPU), a nationally accredited online postsecondary education company (Aspen University), today announced that Chief Executive Officer, Michael Mathews, is scheduled...
Gridsum Reports Unaudited Third Quarter 2016 Financial Results
Nov 21, 2016 21:01 pm UTC| Business
BEIJING, Nov. 21, 2016 -- Gridsum Holding Inc. (“Gridsum” or the “Company”) (NASDAQ:GSUM), a leading provider of cloud-based data analytics solutions in China, today reported results for its third quarter ended...
Integra LifeSciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
Nov 21, 2016 21:01 pm UTC| Business
PLAINSBORO, N.J., Nov. 21, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART)today announced that it will present at the following conference in November: At 10:00M ET on Tuesday, November 29, 2016, Mr....
Nov 21, 2016 20:47 pm UTC| Business
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for relapsed or refractory multiple myeloma Financial guidance...